Additionally, TROPION-Breast04 is a phase III clinical trial examining the efficacy and safety of neoadjuvant Dato-DXd and durvalumab, followed by adjuvant durvalumab treatment in patients with early-stage TNBC or HR-low/HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.